Nkarta Receives FDA Approval for Outpatient NKX019 Dosing in Autoimmune Disease Treatment

Key Takeaways

• FDA approves outpatient dosing of NKX019, allowing treatment in community rheumatology centers instead of specialized facilities
• Patients can now receive redosing in both Ntrust-1 and Ntrust-2 clinical studies, improving treatment flexibility
• Rheumatoid arthritis cohort added to Ntrust-2 study with initial data expected at medical meeting in 2026

---

FDA Breakthrough Expands NKX019 Access

Nkarta, Inc. (Nasdaq: NKTX) announced on April 15, 2026, that the FDA has agreed to allow outpatient dosing of its experimental cell therapy NKX019 for autoimmune diseases. This regulatory milestone enables treatment delivery in community rheumatology centers, significantly expanding patient access beyond specialized medical facilities.

Treatment Expansion and Patient Benefits

The FDA agreement represents a major advancement in making engineered cell therapy more accessible to patients with autoimmune conditions. By moving treatment from inpatient to outpatient settings, Nkarta addresses a critical barrier that often prevents patients from accessing innovative therapies due to geographic or logistical constraints.

The company will continue dosing at the 4 billion cell dose level, delivering 12 billion cells across a 3-dose treatment cycle. This dosing strategy has shown promising results in earlier phases of clinical development.

Clinical Trial Updates

Both the Ntrust-1 and Ntrust-2 studies will now include the option to redose patients, providing physicians with greater flexibility in treatment protocols. Additionally, Nkarta is expanding the Ntrust-2 study to include a rheumatoid arthritis cohort, broadening the potential patient population that could benefit from NKX019.

The South San Francisco-based biotechnology company expects to present initial data from these expanded studies at a major medical meeting later in 2026, which could provide crucial insights into the therapy’s effectiveness across different autoimmune conditions.

Market Impact and Future Outlook

This regulatory advancement positions Nkarta competitively in the growing cell therapy market for autoimmune diseases. The ability to deliver treatment in community settings could accelerate patient enrollment and reduce healthcare costs, potentially making NKX019 a more attractive option for both patients and healthcare systems.

The expanded access model may also serve as a blueprint for other cell therapy companies seeking to move beyond traditional hospital-based treatment paradigms.

---

Frequently Asked Questions

What does outpatient dosing mean for patients receiving NKX019?

Patients can now receive NKX019 treatment at community rheumatology centers instead of being required to visit specialized inpatient facilities, reducing travel burden and making the therapy more accessible.

When will initial data from the expanded NKX019 studies be available?

Nkarta expects to present initial data from both Ntrust-1 and Ntrust-2 studies at a medical meeting sometime in 2026, though the specific conference and timing have not been disclosed.

How does NKX019 compare to existing autoimmune disease treatments?

NKX019 is an engineered cell therapy that represents a novel approach compared to traditional small molecule drugs or biologics, potentially offering longer-lasting effects through cellular reprogramming of the immune system.